Glioblastoma Multiforme
Conditions
Keywords
Glioblastoma Multiforme
Brief summary
This is a phase 2, multicenter study to determine the safety and efficacy of ICT-107 in treating a type of brain tumor called Glioblastoma Multiforme (GBM). ICT-107 is an immunotherapy in which the patient's immune response will be stimulated to kill the tumor cells. Patients must be newly diagnosed with GBM and not yet received chemoradiation. Some of the patient's white blood cells (WBC) will be removed and cultured in a laboratory with purified antigens, similar to those on GBM cells. The patient's own WBC/DC that have been exposed to the tumor antigens will then be given back to the patient as a vaccine over several months. The goal is for the ICT-107 vaccine to stimulate the patient's immune response to kill the remaining GBM tumor cells after surgery and chemotherapy.
Detailed description
The proposed phase 2 study is a randomized, double blind, controlled study of the safety and efficacy of ICT-107 in newly diagnosed patients with glioblastoma multiforme (GBM) following resection and chemoradiation. The phase 1 clinical trial demonstrated safety and promising efficacy in a small, open-label study. The purpose of this study is to provide information from a larger, controlled clinical trial. Patients must be newly diagnosed with GBM and not yet received chemoradiation. Patients will have had tumor resection, magnetic resonance imaging (MRI) and tumor assessment prior to enrollment into the study. Post surgical treatment consists of 6 weeks of chemotherapy (TMZ) and radiation followed by a washout period. After Screening and informed consent, patients will undergo apheresis at the study site for collection of peripheral blood mononuclear cells (PBMCs). Apheresis product will be sent to a central site where monocytes will be purified and cultured into dendritic cells (DC). DC will be pulsed with synthetic peptides that correspond to immunogenic epitopes of tumor antigens. The pulsed dendritic cells will then be aliquoted and frozen before shipping back to the site. Patients will have the autologous DCs reinfused intradermally. A control group will receive unpulsed autologous DC. Patients will be randomized by age in a 2:1 ratio to ICT-107 or control.Patients will receive at least four intradermal injections of the ICT-107 vaccine and additional vaccine during a maintenance phase. The primary objective is to compare overall survival (OS) and progression free survival (PFS) in patients when treated with ICT-107 versus Control.
Interventions
BIOLOGICALICT-107
Autologous dendritic cells pulsed with immunogenic antigens
BIOLOGICALPlacebo DC
Autologous dendritic cells (DC) that have not been pulsed with antigens
Sponsors
Precision Life Sciences Group
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Confirmed, initial diagnosis of GBM. Patients must be newly diagnosed with GBM and not yet received chemoradiation. 2. ≥ 18 years of age 3. HLA-A1 or HLA-A2 positive 4. KPS score of ≥ 70% 5. Baseline hematologic studies and chemistry profiles must meet the following criteria: Hemoglobin (Hgb) \> 9.9 g/dL total granulocyte count \> than 1000/mm3 platelet count \> 100,000/mm3 blood urea nitrogen (BUN) \< 30 mg/dL creatinine \< 2 mg/dL alkaline phosphatase (ALP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 4x upper limit of normal (ULN) prothrombin time (PT) and activated partial thromboplastin time (PTT) ≤ 1.6x control unless therapeutically warranted 6. Female patients of child-bearing potential must have negative serum pregnancy test 7. If not surgically sterile, male and female patients of childbearing age must use double barrier contraception (hormonal; intrauterine device; barrier) 8. Sufficient paraffin embedded tumor sample for analysis MGMT methylation status 9. Written informed consent, Release of Medical Records Form and Health Insurance Portability and Accountability Act (HIPAA) reviewed and signed by patient or legally authorized representatives
Exclusion criteria
1. Recurrent disease 2. Radiosurgery including Gamma Knife, linear accelerator based radiosurgery, CyberKnife and placement of Gliadel wafer 3. Presence of any other active malignancy or prior history of malignancy (except for basal cell carcinoma of the skin) 4. Severe pulmonary, cardiac or other systemic disease 5. Congestive heart failure Class III or IV according to New York Heart Association (NYHA) 6. Presence of an acute infection requiring active treatment with antibiotics/antivirals; prophylactic administration is allowed 7. Known history of an autoimmune disorder 8. Known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS) related illness or other serious medical illness 9. Breastfeeding 10. Received any other therapeutic investigational agent within 30 days of enrollment 11. Reduction of steroids (dexamethasone) to a maximum of 2 mg twice a day (BID) prior to the first administration of study vaccine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | 2 -3 years | The objective is to compare overall survival (OS) in patients when treated with ICT 107 versus Control. OS defined as the time from randomization until date of death or the last date patient known alive (if death is not observed) All randomized patients are included in Intent to Treat analysis |
| Overall Survival in HLA-A2 Patients | 2-3 years | Overall survival in a predefined subpopulation. All randomized patients are included in intent to treat analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 2-3 years | Secondary Endpoints * PFS is defined as the time from randomization until the date of documented progressive disease (PD) or death, whichever occurs first, or last date known alive and progression free if progression or death is not observed. * Population is all randomized patients ITT. |
| Progression Free Survival in HLA- A2 Patients | 2-3 yers | Progression Free Survival in a prespecified subpopulation of patients with HLA-A2 haplotype. Intent to treat population includes all randomized patients. PFS is defined as the time from randomization until the date of documented progressive disease (PD) or death, whichever occurs first, or last date known alive and progression free if progression or death is not observed |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| ICT-107 Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens
ICT-107: Autologous dendritic cells pulsed with immunogenic antigens | 81 |
| Placebo Autologous dendritic cells that have not been pulsed with antigens
Placebo DC: Autologous dendritic cells (DC) that have not been pulsed with antigens | 43 |
| Total | 124 |
Baseline characteristics
| Characteristic | ICT-107 | Placebo | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 22 Participants | 14 Participants | 36 Participants |
| Age, Categorical Between 18 and 65 years | 59 Participants | 29 Participants | 88 Participants |
| Region of Enrollment United States | 81 participants | 43 participants | 124 participants |
| Sex: Female, Male Female | 37 Participants | 12 Participants | 49 Participants |
| Sex: Female, Male Male | 44 Participants | 31 Participants | 75 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 59 / 80 | 40 / 43 |
| serious Total, serious adverse events | 8 / 80 | 7 / 43 |
Outcome results
Primary
Overall Survival in HLA-A2 Patients
Overall survival in a predefined subpopulation. All randomized patients are included in intent to treat analysis.
Time frame: 2-3 years
Population: Patients with HLA-A2 haplotype
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ICT-107 | Overall Survival in HLA-A2 Patients | 18.3 months of survival |
| Control Dendritic Cells | Overall Survival in HLA-A2 Patients | 12.9 months of survival |
Primary
Overall Survival (OS)
The objective is to compare overall survival (OS) in patients when treated with ICT 107 versus Control. OS defined as the time from randomization until date of death or the last date patient known alive (if death is not observed) All randomized patients are included in Intent to Treat analysis
Time frame: 2 -3 years
Population: Intent to treat include all randomized patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ICT-107 | Overall Survival (OS) | 18.3 months of survival |
| Control Dendritic Cells | Overall Survival (OS) | 16.7 months of survival |
Secondary
PFS
Secondary Endpoints * PFS is defined as the time from randomization until the date of documented progressive disease (PD) or death, whichever occurs first, or last date known alive and progression free if progression or death is not observed. * Population is all randomized patients ITT.
Time frame: 2-3 years
Population: Intent to treat includes all randomized patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ICT-107 | PFS | 11.2 months of progression free survival |
| Control Dendritic Cells | PFS | 9.0 months of progression free survival |
Comparison: Stratified log rank p value stratified for age and MGMT methylation statusp-value: 0.01Log Rank
Secondary
Progression Free Survival in HLA- A2 Patients
Progression Free Survival in a prespecified subpopulation of patients with HLA-A2 haplotype. Intent to treat population includes all randomized patients. PFS is defined as the time from randomization until the date of documented progressive disease (PD) or death, whichever occurs first, or last date known alive and progression free if progression or death is not observed
Time frame: 2-3 yers
Population: HLA-A2 patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ICT-107 | Progression Free Survival in HLA- A2 Patients | 11.2 months of progression free survival |
| Control Dendritic Cells | Progression Free Survival in HLA- A2 Patients | 7.2 months of progression free survival |
p-value: 0.033Log Rank